The VentureMed Group

In 2012, practicing vascular surgeon, John P. Pigott, MD, FACS realized there was an unmet need in vessel preparation for the treatment of peripheral artery disease (PAD). With support from Promedica Innovations, Dr. Pigott founded the VentureMed Group to design, develop, and market cost-effective interventional devices to improve patient outcomes and reduce the overall cost of care for the provider and the procedure.

VentureMed Group, Inc is pleased to be a member of the Promedica Innovations Incubator in Toledo, Ohio - a state-of-the-art medical device development and commercialization center.

VentureMed Group has received ISO 13485 Certification for its Quality System.

Management Team

John P. Pigott, MD

Founder, Chief Science Officer

John P. Pigott, MD, FACS, is the founder and chief science officer of VentureMed Group. He is the past director of endovascular surgery at the Jobst Vascular Institute and current Chief Innovation Officer for ProMedica Health Systems in Toledo, Ohio. Dr. Pigott previously completed a fellowship in vascular surgery at the Mayo Clinic. With more than 50 peer-reviewed publications and presentations to his credit, he has spent more than 20 years in the endovascular arena.

Gary Smith

Chief Executive Officer

As chief executive officer of VentureMed Group, Gary Smith, brings 30 years of business leadership experience in the medical device, equipment and diagnostics industry to the company. He has successfully led three medical device start-ups from concept through market entry to sales growth. Prior to joining VentureMed, he served as chief executive officer of PrognostiX (Cleveland Heart Lab) and CleveX, both spinouts from Cleveland Clinic Innovations.

Dave Cox

VP of Sales and Marketing

Dave Cox has over 25 years of experience in medical device and biotech pharmaceutical sales and sales management including 19 years in the endovascular device space. From 2013 to 2016, Dave was Vice President of Sales, Sales Operations and Sales Training for Covidien's peripheral teams leading both the endo-arterial and endo-venous businesses. In 2016, post buy-out, he strategically guided the ev3 peripheral portfolios from Covidien to Medtronic. Over his career Mr. Cox has led expansions of sales teams, integrations post company mergers, and launched new innovative technologies and key product portfolio extensions. Previously he served as Regional Sales Manager, Area Director of Sales, and Senior Director of Corporate Accounts for Covidien, ev3, and Microvena. He holds a BBA in Business Administration from James Madison University.

Follow Us: